Samsung Bioepis Initiates P-III Trial for Ontruzant in China

 Samsung Bioepis Initiates P-III Trial for Ontruzant in China

Samsung Bioepis, Reports, Availability, Brenzys, biosimilar, etanercept, Brazil

 Shots:

  • The P-III study involves assessing of SB3 vs Herceptin in 208 Chinese breast cancer patients and plans to evaluate its safety and efficacy
  • Samsung plans to conduct the trial in collaboration with AffaMed Therapeutics, a Chinese venture established by C-Bridge Capital
  • Ontruzant is a (biosimilar, trastuzumab) and is targeted to treat patients with early breast cancer, metastatic breast cancer, and metastatic gastric cancer and is also approved in the EU. Additionally, Samsung Bioepis has four biosimilars SB3 (Herceptin), SB11 ( Lucentis), SB12 ( Soliris), and SB15 ( Eylea)

Click here to read full press release/ article | Ref: Samsung Bioepis | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post